The new Sublative iD™ Focal Tip ensures Company's commitment to elōs Plus™, eTwo™ and eMatrix™ customers by expanding treatment options for their patients
IRVINE, California, December 11, 2012 /PRNewswire/ --
Syneron Medical Ltd. (NASDAQ: ELOS), http://www.syneron.com, the global leader in medical aesthetic products and technologies, announced the launch of a new Sublative iD™ Focal Tip for challenging treatment areas such as the nasolabial fold ("smile lines") and periorbital rim ("around the eyes"). The new Sublative iD Focal Tip will be available for use on all of Syneron's proprietary Sublative™ compatible systems, which includes elōs Plus™, eTwo™ and eMatrix™.
"We are pleased to provide our customers with the new Sublative iD Focal Tip for use with Syneron's unique Sublative treatment systems. This offering was developed to meet the needs of our customers and expand their treatment capabilities to better serve their patients," said Louis P. Scafuri, Chief Executive Officer at Syneron. " This new tip broadens the applications of our sublative hand piece which, in turn, expands our customers ROI and profitability from the eMatrix, eTwo and elōs Plus devices."
The new Sublative iD Focal Tip features an array of 44 pins on a re-connectable compact tip design that is compatible with any Sublative applicator. "Many of my patients, particularly my younger patients, wish to consider non-surgical as well as surgical options for improvement in the early signs of aging around their eyes," said Alan Gold, M.D., F.A.C.S board certified plastic surgeon in Great Neck, New York. "Using energy-based devices to treat around the periorbital area has previously been technically challenging primarily due to the size of the available applicators. However, the new Sublative iD Focal Tip has been intelligently designed for greater maneuverability and better fit in the smaller, harder to contour areas making it an attractive option which has allowed me to expand the application of Sublative treatment in my practice."
For more information about the new Sublative iD Focal Tip or any of Syneron's broad product offering, visit http://www.syneron.com.
About Syneron Medical Ltd.
Syneron Medical Ltd. - a company devoted to real technology, real science and real results - is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. The Company's aspiration and commitment to innovation expands Syneron's offering beyond medical device into the largest in-demand applications in beauty - skin lightening. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The company markets and services and supports its products in 86 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide. Additional information can be found at http://www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "anticipates," "plans," "expects," "may," "will," "would," "intends," "estimates" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the businesses of Syneron and Candela may not be integrated successfully; the risk that the merger transaction with Candela may involve unexpected costs or unexpected liabilities; the risk that synergies from the merger transaction may not be fully realized or may take longer to realize than expected; the risk that disruptions from the merger transaction make it more difficult to maintain relationships with customers, employees, or suppliers; as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
SOURCE Syneron Medical Ltd.